Back to Newsroom

Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL

Neratinib Graduates from I-SPY 2 TRIAL

LOS ANGELES, Calif., April 7, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced the presentation of positive results from the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” was presented today at the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials.”

Click here to read more